FDA Converts to Full Approval Indication for Keytruda (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors

RAHWAY, N.J.--(BUSINESS WIRE) March 29, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Keytruda, Merck’s anti-PD-1...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news